Summary: New analysis from the Framingham Heart Study finds complex links between blood lipid profiles and the risk of developing Alzheimer’s disease, the leading cause of dementia worldwide. The investigators report that higher concentrations of small dense LDL cholesterol (sdLDL‑C) — a form of “bad” cholesterol associated with heart disease — were linked to an increased risk of Alzheimer’s, while higher levels of the dietary fat transport marker ApoB48 were associated with lower risk. Unexpectedly, participants with the lowest levels of high‑density lipoprotein cholesterol (HDL‑C), commonly called “good” cholesterol, had a lower incidence of Alzheimer’s in this cohort.
These findings underscore the complex and sometimes divergent roles that different lipoproteins appear to play in cardiovascular health versus brain health. The results suggest that specific blood lipid markers might contribute to improved risk stratification for Alzheimer’s disease and could point to potential avenues for prevention research.
Key facts
- Small dense LDL‑C (sdLDL‑C): A 1 standard deviation increase in sdLDL‑C was associated with a 21% higher risk of incident Alzheimer’s disease (hazard ratio 1.21, 95% CI 1.01–1.45).
- ApoB48: A 1 standard deviation increase in ApoB48 concentration, a marker for intestinal fat transport, was associated with a 22% lower risk of developing Alzheimer’s (hazard ratio 0.78, 95% CI 0.66–0.93).
- HDL‑C: Participants in the lowest quartile of HDL‑C were 44% less likely to develop Alzheimer’s disease compared with those in the higher three quartiles (hazard ratio 0.56, 95% CI 0.33–0.95).
Source: UT Southwestern
Overview
Researchers led by the University of Texas Health Science Center at San Antonio examined long‑term data from more than 800 older adults enrolled in the Framingham Heart Study to evaluate how different circulating lipoproteins relate to later development of Alzheimer’s disease. The goal was to clarify physiologic links between cardiovascular risk factors and dementia, and to identify blood lipid signals that might help predict or modify Alzheimer’s risk.
Study population and approach
This community‑based analysis focused on 822 Framingham participants who were 60 years or older and free of dementia at baseline (1985–1988). The group had a mean age of 72.5 years (SD 3.7) and included 538 women (65.5%). Lipoprotein measurements taken during the mid‑ to late‑1980s included HDL‑C, LDL‑C, small dense LDL‑C (sdLDL‑C), lipoprotein(a), apolipoprotein B (ApoB) and the ApoB isoform ApoB48. Participants were followed for cognitive outcomes through 2020, with a median follow‑up of about 12.6 years; during that time 128 participants received a first diagnosis of Alzheimer’s disease.
Key results
The analysis used Cox proportional hazards models adjusted for baseline age and sex. Higher sdLDL‑C concentrations were associated with greater Alzheimer’s risk: each 1 standard deviation increase in ln(sdLDL‑C) conferred a 21% higher risk. In contrast, higher ApoB48 concentrations were associated with reduced risk: each 1 standard deviation increase in ln(ApoB48) corresponded to a 22% lower risk. When lipoprotein measures were examined by quartiles or medians, participants in the lowest HDL‑C quartile were substantially less likely to develop Alzheimer’s than those in the upper quartiles, and those with sdLDL‑C below the median had a lower incidence compared with those above the median.
Interpretation and implications
The study highlights that lipoprotein metabolism may influence brain aging in ways that are distinct from its role in cardiovascular disease. Small, dense LDL particles — long implicated in atherosclerosis — were associated with higher Alzheimer’s risk, suggesting overlapping vascular and neurodegenerative pathways. At the same time, the inverse relationship seen with ApoB48 and the surprising finding for lower HDL‑C invite further investigation into the mechanisms that connect intestinal lipid transport, cholesterol particle composition, and neurodegeneration.
While observational, these results support the idea that detailed blood lipid profiling could contribute to Alzheimer’s risk assessment and motivate targeted research on lipid‑modifying strategies for dementia prevention. The authors note that future studies are needed to replicate these associations, explore causality, and determine whether interventions that alter specific lipoproteins affect dementia outcomes.
About this research
Author: Steven Lee
Source: UT Southwestern
Contact: Steven Lee – UT Southwestern
Image: Image credited to Neuroscience News
Original research: Closed access. “Association of Blood Lipoprotein Levels With Incident Alzheimer’s Disease in Community‑Dwelling Individuals: The Framingham Heart Study” by Sokratis Charisis et al., published in Neurology.
Abstract (condensed)
Background and objectives
Cardiovascular risk factors are established contributors to Alzheimer’s disease (AD) risk. This analysis examined associations between a range of blood lipoprotein levels and incident AD in older, community‑dwelling adults to better understand physiologic links between cardiovascular health and dementia.
Methods
Participants aged 60 or older without dementia and with available lipoprotein data from 1985–1988 were included. Blood levels of HDL‑C, LDL‑C, sdLDL‑C, Lp(a), ApoB and ApoB48 were measured and related to AD incidence through 2020 using Cox models adjusted for age and sex.
Results
Among 822 participants followed for a median of 12.55 years, 128 developed AD. Increased sdLDL‑C was associated with higher AD risk (HR 1.21 per 1 SDU increase), while higher ApoB48 was associated with lower risk (HR 0.78 per 1 SDU increase). Lowest HDL‑C quartile and sdLDL‑C below the median were both associated with reduced AD incidence in this sample.
Discussion
Lower sdLDL‑C and higher ApoB48 were linked with lower AD risk, and those with the lowest HDL‑C had a lower incidence of AD compared with others in the cohort. These findings emphasize the relevance of lipoprotein metabolism to Alzheimer’s risk assessment and point to lipid pathways as potential targets for future prevention strategies.